By the end of treatment (7 months of age) all groups had markedly reduced levels of TNF-α, TNFR1, IL-8, S100 calcium protein A8/A9 complex (S100A8/A9) and CRP compared to untreated MPS VI controls (Figs. 1A–E). The gene discussed is TNFRSF1A; the disease is mucopolysaccharidosis type 6.